Edge-AI and Robotics

DorsaVi Enters the Neuromorphic Computing Space With High-Value IP Acquisition

New processing-in-memory technology pushes the company toward next-generation robotics and edge-AI applications DorsaVi Ltd (ASX: DVL) has taken a significant strategic step with the acquisition of neuromorphic processing-in-memory (PIM) intellectual property from Technion in Israel — technology led by Professor Shahar Kvatinsky, one of the semiconductor industry’s most prominent neuromorphic hardware researchers. This move positions […]

Prescient Advances a Potentially Pivotal Cancer Trial with Multiple Near-Term Catalysts

Phase 2 progress strengthens the commercial outlook for PTX-100 in hard-to-treat T-Cell Lymphoma Prescient Therapeutics (ASX: PTX) is progressing through a critical development phase with its lead drug candidate, PTX-100, currently in a global Phase 2 clinical trial for relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL). The drug is believed to be the only GGT-1 inhibitor […]
Register for the Conference